Allogeneic Transplantation
Non-Cancerous Blood Disorder Trials
COMIRB: 24-2052
Phase 3 Study of Bomedemstat (MK-3543/IMG-7289) v. Best Available
PI: Brandon McMahon
Essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea
COMIRB: 25-07897
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
PI: Mat Angelos
Eligibility criteria are described in the link below.
COMIRB: 25-1016
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
PI: Cassandra Duarte
Eligibility criteria are described in the link below.
COMIRB: 25-1397
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
PI: Brandon McMahon
Eligibility criteria are described in the link below.
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.